Surveillance of Ocular Surface Flora (SURFACE)
Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cataract
Phase: N/A
Status: Completed
Sponsored by: Allergan Official(s) and/or principal investigator(s): Medical Director, Study Director, Affiliation: Allergan
Summary
Topical fluoroquinolones (FQs) have achieved widespread use in ophthalmology for both the
treatment and prophylaxis of ocular infections. The present study is set to determine the
bacteria present on the ocular surface in patients at the time of cataract surgery and to
assess the rate of resistance of ocular isolates to commonly used topical antibiotics.
Clinical Details
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the EyelidPercentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Conjunctiva
Secondary outcome: Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the EyelidPercentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Conjunctiva
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Scheduled to undergo cataract surgery
- Able to provide written informed consent
Exclusion Criteria:
- NSAID in the eye to be swabbed within the past 30 days
- Topical anesthetic, topical antibiotic or antiseptic, or dilating drops in the eye to
the swabbed within the past 7 days
- Over-the-counter artificial tear drops or astringent /redness reliever drops (e. g.,
Visine®, Clear eyes® in the eye to be swabbed on the day of trial
- History of conjunctivitis or any ocular infection within the past 3 months
Locations and Contacts
Salt Lake City, Utah, United States
Additional Information
Starting date: December 2007
Last updated: July 16, 2012
|